## SNDL (SNDL) deep dive — “filings-first” snapshot you can navigate **Context / reporting frame:** SNDL is a Canadian “foreign private issuer” that files its annual report on **Form 40‑F** and reports its consolidated financials in **Canadian dollars (CAD)** under **IFRS**. ["foreign private issuer"](0000950170-25-040545|0) ["Canadian dollars"](0000950170-25-040545|0) ["International Financial Reporting"](0000950170-25-040545|0) **How to use this report (interactive):** - If you reply with **“1”**, I’ll drill into **segment economics** (Liquor Retail vs Cannabis Retail vs Cannabis Ops vs Investments) with a driver tree. - Reply **“2”** for a **risk heatmap** (regulatory, internal controls, SunStream/U.S. exposure, competitive dynamics). - Reply **“3”** for a **capital allocation dossier** (buybacks, share count, dilution/RSUs/warrants, balance sheet flexibility). *(No need to provide extra context—just the number.)* --- # 1) What SNDL is “today” (business model in filings) SNDL’s disclosure frames the company as operating through **four reportable segments**: liquor retail, cannabis retail, cannabis operations, and investments. ["four reportable segments"](0000950170-25-040545|4) A key structural point: SNDL’s filings explicitly note that while operating in Canada, it also has exposure via **SunStream** (a joint venture) that provides growth capital and targets (among other things) U.S.-based cannabis businesses—introducing a distinct risk profile vs the Canadian operating segments. ["Through its joint venture, SunStream"](0000950170-25-040545|4) ["United States based cannabis businesses"](0000950170-25-040545|4) --- # 2) FY2024 “whole company” performance (audited) ### 2.1 Consolidated income statement (FY2024 vs FY2023) **Units:** CAD **$ millions** (computed from CAD $000s). | Metric | FY2024 | FY2023 | Δ YoY | |---|---:|---:|---:| | Net revenue | C$920.45m **(computed)** ["920,448"](0000950170-25-040545|3) | C$909.01m **(computed)** ["909,006"](0000950170-25-040545|3) | +C$11.44m **(computed)** ["920,448"](0000950170-25-040545|3) ["909,006"](0000950170-25-040545|3) | | Gross profit | C$240.33m **(computed)** ["240,331"](0000950170-25-040545|3) | C$190.42m **(computed)** ["190,415"](0000950170-25-040545|3) | +C$49.92m **(computed)** ["240,331"](0000950170-25-040545|3) ["190,415"](0000950170-25-040545|3) | | Operating loss | (C$103.81m) **(computed)** ["Operating loss"](0000950170-25-040545|3) | (C$163.17m) **(computed)** ["(163,171"](0000950170-25-040545|3) | +C$59.36m **(computed)** ["(103,811"](0000950170-25-040545|3) ["(163,171"](0000950170-25-040545|3) | | Net loss | (C$96.20m) **(computed)** ["Net loss"](0000950170-25-040545|3) | (C$176.55m) **(computed)** ["(176,551"](0000950170-25-040545|3) | +C$80.35m **(computed)** ["(96,204"](0000950170-25-040545|3) ["(176,551"](0000950170-25-040545|3) | **Interpretation:** FY2024’s headline improvement is **gross profit expansion** (up ~C$50m) alongside lower operating loss vs FY2023, but the company remains loss-making on an IFRS basis. ["Gross profit"](0000950170-25-040545|3) ["Operating loss"](0000950170-25-040545|3) --- ### 2.2 Segment mix (FY2024 vs FY2023): revenue and operating income (loss) **Units:** CAD $000s (as reported). | Segment | FY2024 net revenue | FY2023 net revenue | FY2024 operating income (loss) | FY2023 operating income (loss) | |---|---:|---:|---:|---:| | Liquor Retail | 555,259 ["555,259"](0000950170-25-040545|3) | 578,895 ["578,895"](0000950170-25-040545|3) | 34,781 ["34,781"](0000950170-25-040545|3) | 24,655 ["24,655"](0000950170-25-040545|3) | | Cannabis Retail | 311,689 ["311,689"](0000950170-25-040545|3) | 289,980 ["289,980"](0000950170-25-040545|3) | (1,742) ["(1,742"](0000950170-25-040545|3) | 4,840 ["4,840"](0000950170-25-040545|3) | | Cannabis Operations | 109,470 ["109,470"](0000950170-25-040545|3) | 87,071 ["87,071"](0000950170-25-040545|3) | 2,663 ["2,663"](0000950170-25-040545|3) | (112,744) ["(112,744"](0000950170-25-040545|3) | | Investments | — ["Investments"](0000950170-25-040545|3) | — ["Investments"](0000950170-25-040545|3) | (50,013) ["(50,013"](0000950170-25-040545|3) | 11,746 ["11,746"](0000950170-25-040545|3) | | Corporate / eliminations | (55,970) ["(55,970"](0000950170-25-040545|3) | (46,940) ["(46,940"](0000950170-25-040545|3) | (89,500) ["(89,500"](0000950170-25-040545|3) | (91,668) ["(91,668"](0000950170-25-040545|3) | | **Total** | **920,448** ["920,448"](0000950170-25-040545|3) | **909,006** ["909,006"](0000950170-25-040545|3) | **(103,811)** ["(103,811"](0000950170-25-040545|3) | **(163,171)** ["(163,171"](0000950170-25-040545|3) | **What jumps out:** - **Liquor Retail** is a material revenue base with **positive operating income** in both years. ["Liquor Retail"](0000950170-25-040545|3) ["Operating income"](0000950170-25-040545|3) - **Cannabis Operations** swings from a large operating loss in FY2023 to **positive operating income in FY2024**, suggesting a major reset in that segment’s economics. ["Cannabis Operations"](0000950170-25-040545|3) ["2,663"](0000950170-25-040545|3) - **Investments** is volatile: FY2024 shows a sizable operating loss in that segment. ["Investments"](0000950170-25-040545|3) ["(50,013"](0000950170-25-040545|3) --- ### 2.3 Balance sheet: “liquidity + leverage” (FY-end) **Units:** CAD $000s. | Metric | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & cash equivalents | 218,359 ["218,359"](0000950170-25-040545|3) | 195,041 ["195,041"](0000950170-25-040545|3) | | Total assets | 1,349,242 ["Total assets"](0000950170-25-040545|3) | 1,473,164 ["1,473,164"](0000950170-25-040545|3) | | Total liabilities | 215,886 ["Total liabilities"](0000950170-25-040545|3) | 243,824 ["243,824"](0000950170-25-040545|3) | | Total shareholders’ equity | 1,133,356 ["Total shareholders’ equity"](0000950170-25-040545|3) | 1,212,069 ["1,212,069"](0000950170-25-040545|3) | **Leverage note (important):** Management states that **as of Dec 31, 2024 the Company had no outstanding bank debt or other debt** (lease liabilities are present, but that statement is about bank/other debt). ["no outstanding bank debt"](0000950170-25-040545|4) --- # 3) FY2024 → 2025 trajectory (interim disclosures): Q2 2025 and H1 2025 SNDL’s mid‑2025 interim MD&A (filed as a 6‑K exhibit) gives a useful “operating cadence” view because it includes both consolidated and segment rollups. ### 3.1 Consolidated Q2 2025 vs Q2 2024 (selected metrics) **Units:** CAD $000s (as reported). | Metric | Q2 2025 | Q2 2024 | |---|---:|---:| | Net revenue | 244,769 ["244,769"](0000950170-25-100450|2) | 228,127 ["228,127"](0000950170-25-100450|2) | | Gross profit | 67,601 ["67,601"](0000950170-25-100450|2) | 58,164 ["58,164"](0000950170-25-100450|2) | | Operating income (loss) | 5,003 ["5,003"](0000950170-25-100450|2) | (4,834) ["(4,834"](0000950170-25-100450|2) | | Net earnings (loss) attributable to owners | 2,885 ["2,885"](0000950170-25-100450|2) | (5,772) ["(5,772"](0000950170-25-100450|2) | | Cash & cash equivalents | 208,224 ["208,224"](0000950170-25-100450|2) | 182,934 ["182,934"](0000950170-25-100450|2) | | Total assets | 1,293,420 ["1,293,420"](0000950170-25-100450|2) | 1,474,055 ["1,474,055"](0000950170-25-100450|2) | **Interpretation:** The interim disclosure shows **positive operating income and positive earnings attributable to owners** in Q2 2025, which (if sustained) would represent a meaningful shift versus the FY2024 IFRS net-loss picture. ["Operating income (loss)"](0000950170-25-100450|2) ["Net earnings (loss)"](0000950170-25-100450|2) --- ### 3.2 Segment scoreboard (Q2 2025 vs Q2 2024) — operating income lens **Units:** CAD $000s (as reported). | Segment | Q2 2025 operating income (loss) | Q2 2024 operating income (loss) | |---|---:|---:| | Liquor Retail | 11,074 ["11,074"](0000950170-25-100450|2) | 8,481 ["8,481"](0000950170-25-100450|2) | | Cannabis Retail | 8,062 ["8,062"](0000950170-25-100450|2) | 3,902 ["3,902"](0000950170-25-100450|2) | | Cannabis Operations | 2,292 ["2,292"](0000950170-25-100450|2) | (1,916) ["(1,916"](0000950170-25-100450|2) | | Investments | 1,833 ["1,833"](0000950170-25-100450|2) | 8,456 ["8,456"](0000950170-25-100450|2) | | Corporate | (18,258) ["(18,258"](0000950170-25-100450|2) | (23,757) ["(23,757"](0000950170-25-100450|2) | | **Total** | **5,003** ["5,003"](0000950170-25-100450|2) | **(4,834)** ["(4,834"](0000950170-25-100450|2) | **What this says in plain English:** in this quarter, **all three operating segments (liquor, cannabis retail, cannabis ops) were positive at operating income**, while “Corporate” remained a large drag. ["Operating income (loss)"](0000950170-25-100450|2) --- # 4) Capital allocation & share structure: buybacks + instruments ### 4.1 Buyback authorization and activity (from FY2024 MD&A) - SNDL disclosed a share repurchase program renewal authorizing up to **$100 million** of repurchases (expiry November 20, 2025). ["repurchase up to $100 million"](0000950170-25-040545|4) ["will expire on November 20, 2025"](0000950170-25-040545|4) - For FY2024: **5.0 million** shares purchased and cancelled at a weighted average price of **$2.61 (US$1.84)**, total cost **$13.2 million** including commissions. ["purchased and cancelled 5.0 million"](0000950170-25-040545|4) ["weighted average price"](0000950170-25-040545|4) ["total cost of $13.2 million"](0000950170-25-040545|4) - From Jan 1, 2025 to Mar 17, 2025: **5.8 million** shares purchased and cancelled at weighted average price **$2.57 (US$1.79)**, total cost **$15.0 million** including commissions. ["purchased and cancelled 5.8 million"](0000950170-25-040545|4) ["total cost of $15.0 million"](0000950170-25-040545|4) ### 4.2 Equity instruments outstanding (dilution map at Dec 31, 2024) **Units:** “(000s)” as disclosed. | Instrument | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Common shares | 263,022 ["263,022"](0000950170-25-040545|4) | 262,776 ["262,776"](0000950170-25-040545|4) | | RSUs | 9,371 ["9,371"](0000950170-25-040545|4) | 8,630 ["8,630"](0000950170-25-040545|4) | | Stock options | 572 ["572"](0000950170-25-040545|4) | 854 ["854"](0000950170-25-040545|4) | | Derivative warrants | 50 ["50"](0000950170-25-040545|4) | 9,933 ["9,933"](0000950170-25-040545|4) | **Why this matters:** even with buybacks, SNDL has meaningful equity-linked instruments (especially RSUs), so “net dilution vs net shrink” becomes a central capital allocation KPI. ["Restricted share units"](0000950170-25-040545|4) ["share repurchase program"](0000950170-25-040545|4) --- # 5) Risk dossier (high-signal items from disclosures) ## 5.1 Internal controls: material weakness (IT general controls) The audited financial statement package includes a description of a **material weakness** related to IT general controls (access restrictions, change controls, documentation/testing). ["not designed effectively"](0000950170-25-040545|3) ["Information technology general controls"](0000950170-25-040545|3) The AIF risk section also highlights this explicitly as a risk factor: a material weakness could lead to misstatements, litigation, impaired capital access, and market confidence issues. ["material weakness"](0000950170-25-040545|2) ["investors to lose confidence"](0000950170-25-040545|2) ## 5.2 SunStream / U.S. cannabis legal exposure (structural risk) SNDL’s AIF states plainly that **cannabis remains illegal under U.S. federal law** and flags strict enforcement as a significant risk for SunStream’s ability to execute its business plan. ["Cannabis remains illegal under U.S. federal law"](0000950170-25-040545|2) It also quantifies balance sheet and P&L exposure to SunStream at FY-end: equity investment **$413.1 million** and share of loss of equity-accounted investees **$65.5 million** (FY2024). ["equity-investment in SunStream of $413.1 million"](0000950170-25-040545|2) ["share of loss"](0000950170-25-040545|2) ## 5.3 Core operating risks: regulation and compliance load The AIF’s risk list is broad, but a few themes recur: - dependence on regulatory approvals/licences and compliance, ["dependent upon regulatory approvals"](0000950170-25-040545|2) - volatility in wholesale cannabis pricing and inflation, ["volatile wholesale cannabis prices"](0000950170-25-040545|2) - cybersecurity threats, ["cybersecurity threats"](0000950170-25-040545|2) - potential Nasdaq delisting risk (as a generic risk factor they name). ["potential Nasdaq delisting"](0000950170-25-040545|2) --- # 6) My “analyst take” — what to watch like a hawk (filings-grounded) 1) **Is the Q2 2025 profitability signal durable?** The interim disclosure shows operating income turning positive in Q2 2025 at the consolidated level. ["Operating income (loss)"](0000950170-25-100450|2) 2) **Segment quality: operating segments positive vs Corporate drag.** Q2 2025 shows operating profitability across Liquor Retail, Cannabis Retail, and Cannabis Operations, while Corporate remains materially negative. ["Liquor Retail"](0000950170-25-100450|2) ["Cannabis Retail"](0000950170-25-100450|2) ["Cannabis Operations"](0000950170-25-100450|2) ["Corporate"](0000950170-25-100450|2) 3) **Investments volatility (SunStream) can dominate the narrative.** FY2024 shows a large Investments segment operating loss and the AIF quantifies substantial exposure to SunStream, with an explicit U.S. federal illegality risk. ["Investments"](0000950170-25-040545|3) ["(50,013"](0000950170-25-040545|3) ["Cannabis remains illegal"](0000950170-25-040545|2) 4) **Capital allocation math:** buybacks are active, but you should weigh them against ongoing equity-linked instruments (RSUs etc.). ["share repurchase program"](0000950170-25-040545|4) ["Restricted share units"](0000950170-25-040545|4) 5) **Controls remediation is not optional.** The ITGC material weakness is clearly documented and could remain an overhang until conclusively remediated (both operationally and in investor trust). ["material weakness"](0000950170-25-040545|2) ["ITGCs"](0000950170-25-040545|3) --- If you want, reply **“1”**, **“2”**, or **“3”** and I’ll continue the deep dive in that direction using the same filings set (40‑F + exhibits + interim 6‑K MD&A) without asking you for any extra input.

## SNDL (SNDL) deep dive — “filings-first” snapshot you can navigate **Context / reporting frame:** SNDL is a Canadian “foreign private issuer” that files its annual report on **Form 40‑F** and reports its consolidated financials in **Canadian dollars (CAD)** under **IFRS**. ["foreign private issuer"](0000950170-25-040545|0) ["Canadian dollars"](0000950170-25-040545|0) ["International Financial Reporting"](0000950170-25-040545|0) **How to use this report (interactive):** - If you reply with **“1”**, I’ll drill into **segment economics** (Liquor Retail vs Cannabis Retail vs Cannabis Ops vs Investments) with a driver tree. - Reply **“2”** for a **risk heatmap** (regulatory, internal controls, SunStream/U.S. exposure, competitive dynamics). - Reply **“3”** for a **capital allocation dossier** (buybacks, share count, dilution/RSUs/warrants, balance sheet flexibility). *(No need to provide extra context—just the number.)* --- # 1) What SNDL is “today” (business model in filings) SNDL’s disclosure frames the company as operating through **four reportable segments**: liquor retail, cannabis retail, cannabis operations, and investments. ["four reportable segments"](0000950170-25-040545|4) A key structural point: SNDL’s filings explicitly note that while operating in Canada, it also has exposure via **SunStream** (a joint venture) that provides growth capital and targets (among other things) U.S.-based cannabis businesses—introducing a distinct risk profile vs the Canadian operating segments. ["Through its joint venture, SunStream"](0000950170-25-040545|4) ["United States based cannabis businesses"](0000950170-25-040545|4) --- # 2) FY2024 “whole company” performance (audited) ### 2.1 Consolidated income statement (FY2024 vs FY2023) **Units:** CAD **$ millions** (computed from CAD $000s). | Metric | FY2024 | FY2023 | Δ YoY | |---|---:|---:|---:| | Net revenue | C$920.45m **(computed)** ["920,448"](0000950170-25-040545|3) | C$909.01m **(computed)** ["909,006"](0000950170-25-040545|3) | +C$11.44m **(computed)** ["920,448"](0000950170-25-040545|3) ["909,006"](0000950170-25-040545|3) | | Gross profit | C$240.33m **(computed)** ["240,331"](0000950170-25-040545|3) | C$190.42m **(computed)** ["190,415"](0000950170-25-040545|3) | +C$49.92m **(computed)** ["240,331"](0000950170-25-040545|3) ["190,415"](0000950170-25-040545|3) | | Operating loss | (C$103.81m) **(computed)** ["Operating loss"](0000950170-25-040545|3) | (C$163.17m) **(computed)** ["(163,171"](0000950170-25-040545|3) | +C$59.36m **(computed)** ["(103,811"](0000950170-25-040545|3) ["(163,171"](0000950170-25-040545|3) | | Net loss | (C$96.20m) **(computed)** ["Net loss"](0000950170-25-040545|3) | (C$176.55m) **(computed)** ["(176,551"](0000950170-25-040545|3) | +C$80.35m **(computed)** ["(96,204"](0000950170-25-040545|3) ["(176,551"](0000950170-25-040545|3) | **Interpretation:** FY2024’s headline improvement is **gross profit expansion** (up ~C$50m) alongside lower operating loss vs FY2023, but the company remains loss-making on an IFRS basis. ["Gross profit"](0000950170-25-040545|3) ["Operating loss"](0000950170-25-040545|3) --- ### 2.2 Segment mix (FY2024 vs FY2023): revenue and operating income (loss) **Units:** CAD $000s (as reported). | Segment | FY2024 net revenue | FY2023 net revenue | FY2024 operating income (loss) | FY2023 operating income (loss) | |---|---:|---:|---:|---:| | Liquor Retail | 555,259 ["555,259"](0000950170-25-040545|3) | 578,895 ["578,895"](0000950170-25-040545|3) | 34,781 ["34,781"](0000950170-25-040545|3) | 24,655 ["24,655"](0000950170-25-040545|3) | | Cannabis Retail | 311,689 ["311,689"](0000950170-25-040545|3) | 289,980 ["289,980"](0000950170-25-040545|3) | (1,742) ["(1,742"](0000950170-25-040545|3) | 4,840 ["4,840"](0000950170-25-040545|3) | | Cannabis Operations | 109,470 ["109,470"](0000950170-25-040545|3) | 87,071 ["87,071"](0000950170-25-040545|3) | 2,663 ["2,663"](0000950170-25-040545|3) | (112,744) ["(112,744"](0000950170-25-040545|3) | | Investments | — ["Investments"](0000950170-25-040545|3) | — ["Investments"](0000950170-25-040545|3) | (50,013) ["(50,013"](0000950170-25-040545|3) | 11,746 ["11,746"](0000950170-25-040545|3) | | Corporate / eliminations | (55,970) ["(55,970"](0000950170-25-040545|3) | (46,940) ["(46,940"](0000950170-25-040545|3) | (89,500) ["(89,500"](0000950170-25-040545|3) | (91,668) ["(91,668"](0000950170-25-040545|3) | | **Total** | **920,448** ["920,448"](0000950170-25-040545|3) | **909,006** ["909,006"](0000950170-25-040545|3) | **(103,811)** ["(103,811"](0000950170-25-040545|3) | **(163,171)** ["(163,171"](0000950170-25-040545|3) | **What jumps out:** - **Liquor Retail** is a material revenue base with **positive operating income** in both years. ["Liquor Retail"](0000950170-25-040545|3) ["Operating income"](0000950170-25-040545|3) - **Cannabis Operations** swings from a large operating loss in FY2023 to **positive operating income in FY2024**, suggesting a major reset in that segment’s economics. ["Cannabis Operations"](0000950170-25-040545|3) ["2,663"](0000950170-25-040545|3) - **Investments** is volatile: FY2024 shows a sizable operating loss in that segment. ["Investments"](0000950170-25-040545|3) ["(50,013"](0000950170-25-040545|3) --- ### 2.3 Balance sheet: “liquidity + leverage” (FY-end) **Units:** CAD $000s. | Metric | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & cash equivalents | 218,359 ["218,359"](0000950170-25-040545|3) | 195,041 ["195,041"](0000950170-25-040545|3) | | Total assets | 1,349,242 ["Total assets"](0000950170-25-040545|3) | 1,473,164 ["1,473,164"](0000950170-25-040545|3) | | Total liabilities | 215,886 ["Total liabilities"](0000950170-25-040545|3) | 243,824 ["243,824"](0000950170-25-040545|3) | | Total shareholders’ equity | 1,133,356 ["Total shareholders’ equity"](0000950170-25-040545|3) | 1,212,069 ["1,212,069"](0000950170-25-040545|3) | **Leverage note (important):** Management states that **as of Dec 31, 2024 the Company had no outstanding bank debt or other debt** (lease liabilities are present, but that statement is about bank/other debt). ["no outstanding bank debt"](0000950170-25-040545|4) --- # 3) FY2024 → 2025 trajectory (interim disclosures): Q2 2025 and H1 2025 SNDL’s mid‑2025 interim MD&A (filed as a 6‑K exhibit) gives a useful “operating cadence” view because it includes both consolidated and segment rollups. ### 3.1 Consolidated Q2 2025 vs Q2 2024 (selected metrics) **Units:** CAD $000s (as reported). | Metric | Q2 2025 | Q2 2024 | |---|---:|---:| | Net revenue | 244,769 ["244,769"](0000950170-25-100450|2) | 228,127 ["228,127"](0000950170-25-100450|2) | | Gross profit | 67,601 ["67,601"](0000950170-25-100450|2) | 58,164 ["58,164"](0000950170-25-100450|2) | | Operating income (loss) | 5,003 ["5,003"](0000950170-25-100450|2) | (4,834) ["(4,834"](0000950170-25-100450|2) | | Net earnings (loss) attributable to owners | 2,885 ["2,885"](0000950170-25-100450|2) | (5,772) ["(5,772"](0000950170-25-100450|2) | | Cash & cash equivalents | 208,224 ["208,224"](0000950170-25-100450|2) | 182,934 ["182,934"](0000950170-25-100450|2) | | Total assets | 1,293,420 ["1,293,420"](0000950170-25-100450|2) | 1,474,055 ["1,474,055"](0000950170-25-100450|2) | **Interpretation:** The interim disclosure shows **positive operating income and positive earnings attributable to owners** in Q2 2025, which (if sustained) would represent a meaningful shift versus the FY2024 IFRS net-loss picture. ["Operating income (loss)"](0000950170-25-100450|2) ["Net earnings (loss)"](0000950170-25-100450|2) --- ### 3.2 Segment scoreboard (Q2 2025 vs Q2 2024) — operating income lens **Units:** CAD $000s (as reported). | Segment | Q2 2025 operating income (loss) | Q2 2024 operating income (loss) | |---|---:|---:| | Liquor Retail | 11,074 ["11,074"](0000950170-25-100450|2) | 8,481 ["8,481"](0000950170-25-100450|2) | | Cannabis Retail | 8,062 ["8,062"](0000950170-25-100450|2) | 3,902 ["3,902"](0000950170-25-100450|2) | | Cannabis Operations | 2,292 ["2,292"](0000950170-25-100450|2) | (1,916) ["(1,916"](0000950170-25-100450|2) | | Investments | 1,833 ["1,833"](0000950170-25-100450|2) | 8,456 ["8,456"](0000950170-25-100450|2) | | Corporate | (18,258) ["(18,258"](0000950170-25-100450|2) | (23,757) ["(23,757"](0000950170-25-100450|2) | | **Total** | **5,003** ["5,003"](0000950170-25-100450|2) | **(4,834)** ["(4,834"](0000950170-25-100450|2) | **What this says in plain English:** in this quarter, **all three operating segments (liquor, cannabis retail, cannabis ops) were positive at operating income**, while “Corporate” remained a large drag. ["Operating income (loss)"](0000950170-25-100450|2) --- # 4) Capital allocation & share structure: buybacks + instruments ### 4.1 Buyback authorization and activity (from FY2024 MD&A) - SNDL disclosed a share repurchase program renewal authorizing up to **$100 million** of repurchases (expiry November 20, 2025). ["repurchase up to $100 million"](0000950170-25-040545|4) ["will expire on November 20, 2025"](0000950170-25-040545|4) - For FY2024: **5.0 million** shares purchased and cancelled at a weighted average price of **$2.61 (US$1.84)**, total cost **$13.2 million** including commissions. ["purchased and cancelled 5.0 million"](0000950170-25-040545|4) ["weighted average price"](0000950170-25-040545|4) ["total cost of $13.2 million"](0000950170-25-040545|4) - From Jan 1, 2025 to Mar 17, 2025: **5.8 million** shares purchased and cancelled at weighted average price **$2.57 (US$1.79)**, total cost **$15.0 million** including commissions. ["purchased and cancelled 5.8 million"](0000950170-25-040545|4) ["total cost of $15.0 million"](0000950170-25-040545|4) ### 4.2 Equity instruments outstanding (dilution map at Dec 31, 2024) **Units:** “(000s)” as disclosed. | Instrument | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Common shares | 263,022 ["263,022"](0000950170-25-040545|4) | 262,776 ["262,776"](0000950170-25-040545|4) | | RSUs | 9,371 ["9,371"](0000950170-25-040545|4) | 8,630 ["8,630"](0000950170-25-040545|4) | | Stock options | 572 ["572"](0000950170-25-040545|4) | 854 ["854"](0000950170-25-040545|4) | | Derivative warrants | 50 ["50"](0000950170-25-040545|4) | 9,933 ["9,933"](0000950170-25-040545|4) | **Why this matters:** even with buybacks, SNDL has meaningful equity-linked instruments (especially RSUs), so “net dilution vs net shrink” becomes a central capital allocation KPI. ["Restricted share units"](0000950170-25-040545|4) ["share repurchase program"](0000950170-25-040545|4) --- # 5) Risk dossier (high-signal items from disclosures) ## 5.1 Internal controls: material weakness (IT general controls) The audited financial statement package includes a description of a **material weakness** related to IT general controls (access restrictions, change controls, documentation/testing). ["not designed effectively"](0000950170-25-040545|3) ["Information technology general controls"](0000950170-25-040545|3) The AIF risk section also highlights this explicitly as a risk factor: a material weakness could lead to misstatements, litigation, impaired capital access, and market confidence issues. ["material weakness"](0000950170-25-040545|2) ["investors to lose confidence"](0000950170-25-040545|2) ## 5.2 SunStream / U.S. cannabis legal exposure (structural risk) SNDL’s AIF states plainly that **cannabis remains illegal under U.S. federal law** and flags strict enforcement as a significant risk for SunStream’s ability to execute its business plan. ["Cannabis remains illegal under U.S. federal law"](0000950170-25-040545|2) It also quantifies balance sheet and P&L exposure to SunStream at FY-end: equity investment **$413.1 million** and share of loss of equity-accounted investees **$65.5 million** (FY2024). ["equity-investment in SunStream of $413.1 million"](0000950170-25-040545|2) ["share of loss"](0000950170-25-040545|2) ## 5.3 Core operating risks: regulation and compliance load The AIF’s risk list is broad, but a few themes recur: - dependence on regulatory approvals/licences and compliance, ["dependent upon regulatory approvals"](0000950170-25-040545|2) - volatility in wholesale cannabis pricing and inflation, ["volatile wholesale cannabis prices"](0000950170-25-040545|2) - cybersecurity threats, ["cybersecurity threats"](0000950170-25-040545|2) - potential Nasdaq delisting risk (as a generic risk factor they name). ["potential Nasdaq delisting"](0000950170-25-040545|2) --- # 6) My “analyst take” — what to watch like a hawk (filings-grounded) 1) **Is the Q2 2025 profitability signal durable?** The interim disclosure shows operating income turning positive in Q2 2025 at the consolidated level. ["Operating income (loss)"](0000950170-25-100450|2) 2) **Segment quality: operating segments positive vs Corporate drag.** Q2 2025 shows operating profitability across Liquor Retail, Cannabis Retail, and Cannabis Operations, while Corporate remains materially negative. ["Liquor Retail"](0000950170-25-100450|2) ["Cannabis Retail"](0000950170-25-100450|2) ["Cannabis Operations"](0000950170-25-100450|2) ["Corporate"](0000950170-25-100450|2) 3) **Investments volatility (SunStream) can dominate the narrative.** FY2024 shows a large Investments segment operating loss and the AIF quantifies substantial exposure to SunStream, with an explicit U.S. federal illegality risk. ["Investments"](0000950170-25-040545|3) ["(50,013"](0000950170-25-040545|3) ["Cannabis remains illegal"](0000950170-25-040545|2) 4) **Capital allocation math:** buybacks are active, but you should weigh them against ongoing equity-linked instruments (RSUs etc.). ["share repurchase program"](0000950170-25-040545|4) ["Restricted share units"](0000950170-25-040545|4) 5) **Controls remediation is not optional.** The ITGC material weakness is clearly documented and could remain an overhang until conclusively remediated (both operationally and in investor trust). ["material weakness"](0000950170-25-040545|2) ["ITGCs"](0000950170-25-040545|3) --- If you want, reply **“1”**, **“2”**, or **“3”** and I’ll continue the deep dive in that direction using the same filings set (40‑F + exhibits + interim 6‑K MD&A) without asking you for any extra input.